Positive preliminary results for Eli Lilly’s efsitora alfa continue to build the case for this once-weekly insulin in type 2 diabetes patients. Lilly is trying to catch up to Novo Nordisk’s once weekly insulin icodec, which is commercially available in several markets around the world but is not yet approved by the FDA. The post…
[Sponsored] In a webinar sponsored by fintech business Mercury, investors from Breyer Capital and MBX Capital shared their startup trend perspectives on AI, valuation, and alternative funding. The post Investors Share How Early Stage Healthcare and Life Science Startups Can Make the Most of New Opportunities appeared first on MedCity News.
If you or someone you know may be experiencing a mental health crisis, contact the 988 Suicide & Crisis Lifeline by dialing or texting “988.” Someone in America dies by suicide every 11 minutes. It’s that common. But that doesn’t make it normal. Humans have evolved over centuries to survive. So when people try to kill themselves, something has gone wrong….
Booster Therapeutics’ small molecules activate the 20S proteasome, a component of cells that gets rid of misfolded proteins. Parkinson’s and Alzheimer’s are potential disease targets for the startup, which launched with $15 million in seed financing. The post Startup Booster Therapeutics Launches to Usher In Next Wave of Protein-Degrading Drugs appeared first on MedCity News.
Gilead Sciences is acquiring LEO Pharma’s oral small molecule inhibitors of STAT6, a protein key to two validated inflammation pathways. Other STAT6 drug developers include Kymera Therapeutics and Sanofi-partnered Recludix Pharma, which is presenting this week during the J.P. Morgan Healthcare Conference. The post Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt…
By MIKE MAGEE When I asked my brilliant literary agent, Jill Kneerim, when I would know that my book proposal was ready for submission, she replied directly, “It will be ready when I say it is ready.” Eleven months later, in April, 2018, she finally green lit the project, and two weeks after that, in…
How much of precision interventional psychiatry can actually happen remotely, and where does the model hit a wall? The answer is potentially more nuanced than the conventional framing suggests. The post Can Precision Psychiatry Be Delivered Remotely? The Limits and Opportunities of Telehealth in Interventional Care appeared first on MedCity News.
This issue brief describes recent trends in the number of Medicaid outpatient prescriptions and the spending on those drugs and examines how the pandemic and pandemic-era policies may have impacted those trends.
This brief provides an overview of premiums and benefits in Medicare Advantage plans that are available for 2026 and key trends over time.
That is the title of a new paper published in the American Journal of Managed Care (AJMC) with co-authors Jacob Fajnor, Shurui Zhang, and Donald Nichols. The abstract is below. Objectives: To (1) develop a metric that quantitatively measures the risk that utilization management (UM) policies pose to patients and (2) measure the relationship between…